The invention provides non-naturally occurring microbial organisms containing caprolactone pathways having at least one exogenous nucleic acid encoding a butadiene pathway enzyme expressed in a sufficient amount to produce caprolactone. The invention additionally provides methods of using such microbial organisms to produce caprolactone by culturing a non-naturally occurring microbial organism containing caprolactone pathways as described herein under conditions and for a sufficient period of time to produce caprolactone.

A process for forming a flame retardant polymer, as well as the flame retardant polymer, are disclosed. A flame retardant polymer is a polymer that can be resistant to thermal degradation and/or thermal oxidation. A flame retardant polymer can be mixed or otherwise incorporated into a standard polymer to give flame retardancy to the standard polymer. The flame retardant polymers can include polycaprolactone functionalized with flame retardant substituents. The flame retardant substituents can include halides, substituted phosphoryl, and substituted phosphonyl.

A process for forming a flame retardant polymer, as well as the flame retardant polymer, are disclosed. A flame retardant polymer is a polymer that can be resistant to thermal degradation and/or thermal oxidation. A flame retardant polymer can be mixed or otherwise incorporated into a standard polymer to give flame retardancy to the standard polymer. The flame retardant polymers can include polycaprolactone functionalized with flame retardant substituents. The flame retardant substituents can include halides, substituted phosphoryl, and substituted phosphonyl.

The invention provides non-naturally occurring microbial organisms containing caprolactone pathways having at least one exogenous nucleic acid encoding a butadiene pathway enzyme expressed in a sufficient amount to produce caprolactone. The invention additionally provides methods of using such microbial organisms to produce caprolactone by culturing a non-naturally occurring microbial organism containing caprolactone pathways as described herein under conditions and for a sufficient period of time to produce caprolactone.

The invention provides non-naturally occurring microbial organisms containing caprolactone pathways having at least one exogenous nucleic acid encoding a butadiene pathway enzyme expressed in a sufficient amount to produce caprolactone. The invention additionally provides methods of using such microbial organisms to produce caprolactone by culturing a non-naturally occurring microbial organism containing caprolactone pathways as described herein under conditions and for a sufficient period of time to produce caprolactone.

A process for forming a flame retardant polymer, as well as the flame retardant polymer, are disclosed. A flame retardant polymer is a polymer that can be resistant to thermal degradation and/or thermal oxidation. A flame retardant polymer can be mixed or otherwise incorporated into a standard polymer to give flame retardancy to the standard polymer. The flame retardant polymers can include polycaprolactone functionalized with flame retardant substituents. The flame retardant substituents can include halides, substituted phosphoryl, and substituted phosphonyl.

Molecular characterization of disease has become the dominant trend in modern medicine, and it has recently become increasingly important to obtain qPCR, microarray, and next-generation sequencing (NGS) data for both research and clinical applications. Formalin-fixed, paraffin-embedded (FFPE) samples have become the standard way of storing clinical biopsies throughout the world. Unfortunately, the poor quality and quantity of nucleic acids obtained from such specimens has posed severe limitations on the types of studies that can be accomplished. Existing methods for retrieval of the biomolecules from their crosslinked matrices are poorly effective and rely on harsh conditions which further damage the biomolecules being extracted. The invention provides compositions and methods for retrieval, analysis and use of biomolecules, including nucleic acids, from such samples.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

X-A-Y-L-R(I)

which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

X-A-Y-L-R(I)

which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present disclosure provides a process for the preparation of compounds of formula (III), ##STR00001##
compounds of formula (V), ##STR00002##
and corresponding salts of formula (IV). ##STR00003## The compounds made by the methods and processes of the invention are particularly useful for administration in humans and animals.